Status:
UNKNOWN
The Role of 68Ga-FAPI-04 PET/CT as a Problem Solving Imaging Modality in Various Malignancies
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Different Types of Cancer
Eligibility:
All Genders
18-120 years
Phase:
NA
Brief Summary
The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in patients with various malignancies, in whom a diagnostic c...
Eligibility Criteria
Inclusion
- The study population will include up to 50 patients with disease in whom a diagnostic challenge is met, including but not limited to:
- Inconclusive findings on 18F-FDG PET/CT or other imaging modalities.
- Better delineation of tumor extent prior to therapy
- Malignancies known to show variable avidity to FDG and at times, no uptake at all (e.g. Exocrine Pancreatic cancer, Gastric carcinoma, Mucin-producing or Signet-ring carcinoma).
- Patients unable to optimally comply with the required preparation for FDG imaging.
- The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff.
Exclusion
- Age \< 18 years.
- Pregnant females.
- Patients who are reluctant to undergo both FDG and FAPI PET scans.
Key Trial Info
Start Date :
June 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04441606
Start Date
June 11 2020
End Date
July 1 2021
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky medial center
Tel Aviv, Israel